Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven
Randomized controlled trials (RCTs) are the gold standard for testing the safety and efficacy of new drugs and biologicals. The US Food and Drug Administration (FDA) has proactively improved the trial designs to make them scientifically rational while avoiding unnecessary human exposure. Several new...
Saved in:
Main Author: | Sarfaraz K. Niazi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advice to the US FDA to Allow US Pharmacopeia to Create Biological Product Specifications (BPS) to Remove Side-by-Side Analytical Comparisons of Biosimilars with Reference Products
by: Sarfaraz K. Niazi
Published: (2024) -
The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars
by: Sarfaraz K. Niazi
Published: (2023) -
Disallowance analysis through the audit of accounts performed by nurses: an integrative review
by: Cinthia Prates Vigna, et al.
Published: (2020) -
A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
by: Sarfaraz K. Niazi
Published: (2023) -
Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars
by: Sarfaraz K. Niazi, et al.
Published: (2023)